VRTX
Vertex Pharmaceuticals Inc / Ma Health Care Pharmaceutical Preparations S&P 500Nasdaq-100Russell 3000
$558.88Close
$142.0BMarket cap
$409.47 – $558.8852-week range
Nov 2, 2026Next report · after the close
Highlights
Strengths
- In a stage-2 uptrend all 8 trend conditions pass
- Leading the market RS 81 · stronger than 81% of stocks over 12 months
- Near its high at its 52-week high
- Accumulation up-day volume 1.5× down-day volume over 50 sessions
Cautions
- Past its pivot 5.5% above its $529.89 pivot
- Results soon Nov 2, 2026, in 1 day
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
0%
1wk
up 6.7%
price change
1mo
up 6.9%
price change
12-month return
up 33%
market up 11% ·
its own up 23%
F-score
8 / 9
Exceptional
Altman Z
14.30
Low risk
P/E
35.9×
price / earnings
PEG
—
P/E / EPS growth
P/B
7.6×
price / book
Earnings yield
up 3.0%
EBIT / enterprise value
Cheaper than
35%
of the market · expensive
Revenue growth
up 9%
year on year
EPS growth
up 8%
latest quarter · -54 pts
Sales growth
up 12%
latest quarter · +5 pts
ROE
up 23%
return on equity
Free cash margin
up 27%
$3.2B FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
-1.2×
net cash
Interest cover
—EBIT / interest
Piotroski tests
- profits not fully backed by cash
- profitable on its assets
- generating cash from operations
- profitability improving
- reduced long-term debt
- short-term liquidity improved
- no new shares issued
- gross margin widened
- assets working harder
Repair signals
- FCF turned positive ($-790M → $3,194M)
Trade setup
ATR%
2.7%
$15.14 a day · 2×ATR $528.59
RS
81 / 99
vs the universe
Trend
8 / 8
trend template
Relative volume
2.7×
vs 50-day average
Up/down volume
1.53
50 sessions
Implied move
5.8%
by Nov 6, 2026 · report Nov 2, 2026
Contractions
2
11% → 9%
Pivot
$529.89
5.5% above
Volume dry-up
1.3×
10 vs 50 sessions
Trend template · 8 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- No restatement or impairment
- Equity positive
- Interest covered
- No material dilution
- Profits tracking cash
- Margins and revenue not shrinking
Last reported
Aug 3, 2026
Results reaction
Aug 3, 2026-3% vs market2 sessions after results
Options
$5.7M36.7% IV · activity
Financials
- Gross 86%
- Net 33%
- Free cash 27%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $6.2B | $7.6B | $8.9B | $9.9B | $11.0B | $12.0B |
| Gross margin | 88% | 88% | 88% | 87% | 86% | 86% |
| Operating income | $2.9B | $2.8B | $4.3B | $3.8B | -$232.9M | $4.2B |
| Net income | $2.7B | $2.3B | $3.3B | $3.6B | -$535.6M | $4.0B |
| Net margin | 44% | 31% | 37% | 37% | -5% | 33% |
| Earnings per share | $10.29 | $9.01 | $12.82 | $13.89 | -$2.08 | $15.32 |
| Free cash flow | $3.0B | $2.4B | $3.9B | $3.3B | -$790.3M | $3.2B |
| Free cash margin | 48% | 32% | 44% | 34% | -7% | 27% |
| Cash | $6.0B | $6.8B | $10.5B | $10.4B | $4.6B | $5.1B |
| Shareholders' equity | $8.7B | $10.1B | $13.9B | $17.6B | $16.4B | $18.7B |
| Shares outstanding | 259.89m | 254.48m | 257.01m | 257.70m | 256.94m | 253.99m |
Next report
Nov 2, 2026 · after the close
Expected move The move, either way, the option market prices in through the next scheduled report: the at-the-money straddle for the first expiry that contains it, over the price. It includes the days around the report, so it slightly overstates the report alone. Methodology
±5.8%
$522 – $586 by Nov 6, 2026
Usual move The median, over the company's last four reports, of how far the stock moved either way from the close before the filing to the close of the session after it. Methodology
±0.6%
last 4: +0.3% · +0.1% · +6.6% · -0.9%
Expected against usual The move the options price through this report over the move the last four reports delivered. Above 1 the event is priced bigger than the company's own record; below 1, smaller. A price, not a forecast: it says what protection through the report costs, not which way the stock will go. Methodology
Bigger than usual
9.2× the usual move
What options price now
- Expected 1-month range The at-the-money straddle for the expiry nearest a month out, as a share of the price: the move, either way, the option market is pricing by then. The range is the price plus and minus that move; the stock ends inside it a little more often than not. Methodology
- $508 – $600 ±8.2% by Nov 27, 2026
- Swings expected vs recent The daily swings the options are priced for (implied volatility) against the swings the stock actually had over the last 20 sessions (realised volatility). Bigger means options charge for more movement than the stock has been delivering; smaller, less. On a contract row, that contract's own implied volatility over the stock's realised. Methodology
- Bigger 36.7% priced · 30.6% recent
- Next month vs later At-the-money implied volatility for 8-45 day expiries over 46-90 day ones: whether options price the coming month as choppier or calmer than the two after it. Ahead of a report it usually reads choppier, and the extra comes out once the report is out. Methodology
- Choppier
- Crash protection What options that pay off in a fall cost against options that pay off in a rise (the 25-delta skew), compared with this company's own normal - the median of its stored nightly readings, once there are 20 - and with five sessions ago. Protection costs a little more than upside on most shares. More than usual means readers of the chain are paying up to insure against a drop; it does not say which way the stock will go. Methodology
- past week: costs less
Positioning
- Premium traded
- $5.7M calls $4.7M · puts $1.1M · latest session
- 0.23× -0.03 over the week
- Open interest added The change over five sessions in option positions left open overnight, calls and puts. A rise means positions were added. It cannot say whether they were bought or sold, so more calls is not a vote for a rise: a call is as often sold against shares already held. Methodology
- calls -3.35k · puts -542 past week
For options traders: ATM IV 36.7% (+1.0% 1w) · 1m ÷ 3m IV 1.14 · 25Δ skew 4.1 pts · Net GEX $8.0M
Most traded contracts
No contract passed the liquidity filters this week.
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 4, 2026 | Quarterly ↗ | Jun 30, 2026 | 35d |
| May 5, 2026 | Quarterly ↗ | Mar 31, 2026 | 35d |
| Feb 13, 2026 | Annual ↗ | Dec 31, 2025 | 44d |
| Nov 4, 2025 | Quarterly ↗ | Sep 30, 2025 | 35d |
| Aug 5, 2025 | Quarterly ↗ | Jun 30, 2025 | 36d |
| May 6, 2025 | Quarterly ↗ | Mar 31, 2025 | 36d |
| Feb 13, 2025 | Annual ↗ | Dec 31, 2024 | 44d |
| Nov 5, 2024 | Quarterly ↗ | Sep 30, 2024 | 36d |
| Aug 2, 2024 | Quarterly ↗ | Jun 30, 2024 | 33d |
| May 7, 2024 | Quarterly ↗ | Mar 31, 2024 | 37d |
| Feb 15, 2024 | Annual ↗ | Dec 31, 2023 | 46d |
| Nov 7, 2023 | Quarterly ↗ | Sep 30, 2023 | 38d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 20, 2026 | Director or officer change ↗ |
| Sep 1, 2026 | Director or officer change ↗ |
| Aug 3, 2026 | Results ↗ |
| Jul 7, 2026 | Material agreement · Regulation FD · Other events ↗ |
| May 13, 2026 | Director or officer change · Shareholder vote ↗ |
| May 4, 2026 | Results ↗ |
| Apr 29, 2026 | Director or officer change ↗ |
| Mar 31, 2026 | Other events ↗ |
| Feb 12, 2026 | Results ↗ |
| Nov 3, 2025 | Results ↗ |
| Aug 4, 2025 | Results · Director or officer change ↗ |
| May 19, 2025 | Other events ↗ |